← FDA DRUG APPROVALS

FDA ANDA · ANDA087999

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

Sponsor: PUREPAC PHARM

APPLICATION
ANDA087999
TYPE
ANDA
ORIGINAL APPROVAL
1985-11-06
LATEST ACTION
1989-10-02
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDEDiscontinued
HYDROCHLOROTHIAZIDE 25MG, SPIRONOLACTONE 25MG · TABLET · ORAL

Approval history

1989-10-02Labeling · Supplement 5AP
1988-03-15Labeling · Supplement 4AP
1985-11-06OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →